David James VanderWeele

  • 582 Citations
20022023

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

Dr. VanderWeele did his medical and research training at the University of Chicago, where he developed a research program characterizing the heterogeneity and evolution of the cancer genome. He moved to the National Cancer Institute in Bethesda, MD, where he continued to seek to improve the treatment of prostate cancer based on patients’ specific genetic changes. He returned to Chicago in 2018 to join the GU cancer team at Northwestern University, where he continues to translate discoveries made at the bench into improved therapies in the clinic.

Training Experience

2009Residency, University of Chicago
2013Fellowship, University of Chicago

Education/Academic qualification

MD, The University of Chicago

… → 2007

PhD, The University of Chicago

… → 2005

Research interests

  • Bladder Cancer
  • Kidney Cancer / Urinary Tract Cancer
  • Oncology
  • Prostate Cancer

Fingerprint Dive into the research topics where David James VanderWeele is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 14 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

Research Output

  • 582 Citations
  • 16 Article
  • 3 Review article
  • 2 Comment/debate
  • 1 Editorial

Metastatic hormone-sensitive prostate cancer: Clinical decision making in a rapidly evolving landscape of life-prolonging therapy

VanderWeele, D. J., Antonarakis, E. S., Carducci, M. A., Dreicer, R., Fizazi, K., Gillessen, S., Higano, C. S., Morgans, A. K., Petrylak, D. P., Sweeney, C. J. & Hussain, M., Jan 1 2019, In : Journal of Clinical Oncology. 37, 32, p. 2961-2967 7 p.

Research output: Contribution to journalComment/debate

mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy

Gold, S. A., VanderWeele, D. J., Harmon, S., Bloom, J. B., Karzai, F., Hale, G. R., Marhamati, S., Rayn, K. N., Mehralivand, S., Merino, M. J., Gulley, J. L., Bilusic, M., Madan, R. A., Choyke, P. L., Turkbey, B., Dahut, W. & Pinto, P. A., Jun 2019, In : Urologic Oncology: Seminars and Original Investigations. 37, 6, p. 352.e25-352.e30

Research output: Contribution to journalArticle

  • Past, Current, and Future of Immunotherapies for Prostate Cancer

    Boettcher, A. N., Usman, A., Morgans, A., VanderWeele, D. J., Sosman, J. & Wu, J. D., Sep 11 2019, In : Frontiers in Oncology. 9, 884.

    Research output: Contribution to journalReview article

    Open Access
  • 2 Scopus citations

    Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

    Karzai, F., VanderWeele, D. J., Madan, R. A., Owens, H., Cordes, L. M., Hankin, A., Couvillon, A., Nichols, E., Bilusic, M., Beshiri, M. L., Kelly, K., Krishnasamy, V., Lee, S., Lee, M. J., Yuno, A., Trepel, J. B., Merino, M. J., Dittamore, R., Marté, J., Donahue, R. N. & 7 others, Schlom, J., Killian, K. J., Meltzer, P. S., Steinberg, S. M., Gulley, J. L., Lee, J. M. & Dahut, W. L., Dec 4 2018, In : Journal for immunotherapy of cancer. 6, 1, 141.

    Research output: Contribution to journalReview article

    Open Access
  • 19 Scopus citations